634
We herein described an additional patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia who developed tumor lysis syndrome after 10-day treatment with imatinib.
 patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia: Subject; tumor lysis syndrome: Effect; 10-day treatment with imatinib: Treatment; imatinib: Treatment.Drug; 10-day: Treatment.Time_elapsed; BCR-ABL (ela2) positive acute lymphoblastic leukemia: Treatment.Disorder
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 patient with BCR-ABL (ela2) positive acute lymphoblastic leukemia: Subject; tumor lysis syndrome: Effect; 10-day treatment with imatinib: Treatment; imatinib: Treatment.Drug; 10-day: Treatment.Time_elapsed; BCR-ABL (ela2) positive acute lymphoblastic leukemia: Treatment.Disorder